Related Experiment Videos
[Current Streptococcus pyogenes sensitivity responsible for acute tonsillopharyngitis in France]
P Mariani-Kurkdjian1, C Doit, D Deforche
1Service de microbiologie, Hôpital Robert Debré, Paris. patricia.mariani@rdb.ap-hop-paris.fr
Presse Medicale (Paris, France : 1983)
|July 17, 2004
Summary
Group A beta-haemolytic streptococcus (GABHS) tonsillopharyngitis treatment guidelines recommend beta-lactam antibiotics due to sustained GABHS susceptibility. Erythromycin resistance in GABHS strains is increasing, posing a high risk for treatment failure.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Current guidelines for tonsillopharyngitis recommend antibiotics only for Group A beta-haemolytic streptococcus (GABHS) infections diagnosed by rapid tests.
- Empirical antibiotic selection requires ongoing surveillance of GABHS antibiotic resistance patterns.
Purpose:
- To evaluate the in vitro activity of key antibiotics against GABHS.
- To determine the prevalence of antibiotic resistance in GABHS isolates.
Summary:
- Beta-lactam agents (penicillin G, amoxicillin, cefaclor, cefpodoxime, cefuroxime) showed consistent activity with no detected resistance in 93 GABHS isolates.
- Erythromycin and clarithromycin resistance in GABHS increased significantly to 14% in 2002, compared to 6.2% in 1996-1999.
Impact:
- Rising erythromycin resistance necessitates careful consideration for empirical antibiotic therapy in GABHS tonsillopharyngitis.
- Sustained GABHS susceptibility to beta-lactams supports their continued use as first-line treatment.